Intuitive Surgical, Inc. (NASDAQ:ISRG – Get Free Report) EVP Gary Loeb sold 400 shares of the business’s stock in a transaction on Tuesday, November 10th. The stock was sold at an average price of $458.15, for a total value of $183,260.00. Following the completion of the transaction, the executive vice president owned 6,236 shares of the company’s stock, valued at $2,857,023.40. This represents a 6.03% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Intuitive Surgical Price Performance
Intuitive Surgical stock opened at $449.53 on Thursday. Intuitive Surgical, Inc. has a one year low of $328.57 and a one year high of $603.88. The business’s fifty day moving average is $414.76 and its 200 day moving average is $430.83. The stock has a market capitalization of $155.83 billion, a PE ratio of 54.36, a price-to-earnings-growth ratio of 3.10 and a beta of 1.45.
Intuitive Surgical (NASDAQ:ISRG – Get Free Report) last posted its earnings results on Tuesday, October 20th. The medical equipment provider reported $3.00 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.65 by $0.35. Intuitive Surgical had a net margin of 25.54% and a return on equity of 18.17%. The business had revenue of $3.05 billion for the quarter, compared to analysts’ expectations of $2.91 billion. During the same quarter in the prior year, the business earned $2.40 EPS. The business’s revenue for the quarter was up 21.7% compared to the same quarter last year. As a group, sell-side analysts expect that Intuitive Surgical, Inc. will post 9.37 EPS for the current fiscal year.
Institutional Inflows and Outflows
Wall Street Analyst Weigh In
ISRG has been the topic of several research analyst reports. Leerink Partners set a $503.00 price target on Intuitive Surgical and gave the company an “outperform” rating in a report on Wednesday, October 21st. KeyCorp reissued an “overweight” rating on shares of Intuitive Surgical in a report on Wednesday, August 12th. Mizuho dropped their target price on Intuitive Surgical from $415.00 to $400.00 and set a “neutral” rating on the stock in a research report on Wednesday, October 21st. UBS Group restated a “buy” rating on shares of Intuitive Surgical in a research note on Tuesday, October 13th. Finally, Stifel Nicolaus reduced their price target on shares of Intuitive Surgical from $670.00 to $550.00 and set a “buy” rating for the company in a research report on Friday, July 17th. One analyst has rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating, five have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $493.54.
Get Our Latest Analysis on ISRG
About Intuitive Surgical
Intuitive Surgical develops, manufactures and markets robotic-assisted systems for minimally invasive procedures. Its products include da Vinci surgical systems, which allow surgeons to control instruments and a high-definition vision system from a console, as well as the Ion endoluminal system, designed to assist with minimally invasive lung biopsies. The company also provides instruments, accessories, training and support services for its systems. Its technology is used in a range of surgical specialties, including urology, general surgery and gynecology.
Featured Articles
- Five stocks we like better than Intuitive Surgical
- The Post-Midterm Rally Clock Is Ticking—and These 3 AI Stocks Stand Out
- Hims & Hers Bounced Back 9%, But Its Earnings Reveal a Costly Trade-Off
- Palantir’s Real Washington Risk Isn’t the Budget—It’s Oversight
- Keeping AI Cool: AAON Rides the AI Heatwave to Record Growth
Receive News & Ratings for Intuitive Surgical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intuitive Surgical and related companies with MarketBeat.com's FREE daily email newsletter.
